Products
Platform
Research
Market
Learn
Partner
Support
IPO

L

Lincoln Pharmaceuticals Share Price

480.3
-0.85 (-0.18%)
LINCOLN • 26 Dec, 2025 | 03:29 PM
Buywith MTF at 1x leverage

1Y Annualised Return

-38.84%

3Y Annualised Return

12.00%

5Y Annualised Return

15.98%

10Y Annualised Return

7.14%

The current prices are delayed, login or Open Demat Account for live prices.

Lincoln Pharmaceuticals Stock Performance

1W Return-0.68
1Y Return-38.95
Today's Low476
Prev. Close481.15
Mkt Cap (Cr.)962.03
1M Return-6.95
3Y Return40.69
52-Week High869
Open484.40
PE Ratio12.03
6M Return-14.70
Today's High484.4
52-Week Low464.4
Face Value10

Lincoln Pharmaceuticals Company background

Founded in: 1995
Managing director: Mahendra G Patel
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022. The Company commenced commercial production in Mehsana in FY 2025.

Lincoln Pharmaceuticals Financial Highlights


For the full year FY2025–2026, revenue reached ₹645.71 crore and profit touched at ₹82.35 crore.

Lincoln Pharmaceuticals Share Price Today


As of 27 Dec 2025, Lincoln Pharmaceuticals share price is ₹480.3. The stock opened at ₹484.4 and had closed at ₹481.2 the previous day. During today’s trading session, Lincoln Pharmaceuticals share price moved between ₹476.00 and ₹484.40, with an average price for the day of ₹480.20. Over the last 52 weeks, the stock has recorded a low of ₹464.40 and a high of ₹869.00. In terms of performance, Lincoln Pharmaceuticals share price has declined by 14.7% over the past six months and has declined by 38.84% over the last year.
Read More
Lincoln Pharmaceuticals SIP Return Calculator
5,000
Over the past
Total Investment of ₹0
Monthly SIP of 5,000 would have become 0 in 5 years with a gain of 0 (+0.00%)
View details of Market Depth

Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

962.03

Face Value

10

Turnover (in lacs)

35.96

Key Metrics

Qtr Change %
Near 52W Low of ₹464.40
-10.6
Dividend yield 1yr %
Below industry Median
0.4

Lincoln Pharmaceuticals Key Financials

View more
Loading chart...
Lincoln Pharmaceuticals Quarterly Revenue
Lincoln Pharmaceuticals Yearly Revenue
Lincoln Pharmaceuticals Quarterly Net Profit/Loss
Lincoln Pharmaceuticals Yearly Net Profit/Loss

Lincoln Pharmaceuticals Result Highlights

  • Lincoln Pharmaceuticals Ltd reported a 0.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.3%.

  • Its expenses for the quarter were up by 5.9% QoQ and 4.0% YoY.

  • The net profit decreased 27.8% QoQ and decreased 24.1% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 9.98 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals Shareholding Pattern

Promoter
49.8%
Foreign Institutions
4.7%
Public
45.5%

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
480.3
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Day EMA5
482.70
Day EMA10
484.00
Day EMA12
485.00
Day EMA20
490.10
Day EMA26
494.00
Day EMA50
506.40
Day EMA100
524.30
Day EMA200
552.80
Delivery & Volume
Loading chart...

Day

49.30%

Week

62.70%

Month

63.30%

Delivery & Volume

480.23
Pivot
Resistance
First Resistance
484.47
Second Resistance
488.63
Third Resistance
492.87
Support
First Support
476.07
Second support
471.83
Third Support
467.67
Relative Strength Index
39.43
Money Flow Index
39.10
MACD
-9
MACD Signal
-10.18
Average True Range
12.35
Average Directional Index
46.22
Rate of Change (21)
-6.95
Rate of Change (125)
-14.70
Compare

Lincoln Pharmaceuticals Latest News

24 DEC 2025 | Wednesday
14 NOV 2025 | Friday
13 NOV 2025 | Thursday

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account